Shilpa Medicare Limited (NSE: SHILPAMED) secures final approval for OERISTM, the world's first extended-release ondansetron injection, marking a significant.
Shilpa Medicare Limited (NSE: SHILPAMED) stock breaks out, clearing its 6M resistance trendline with a 5% intraday gain. Current price stands at ₹800.15.
Shilpa Medicare Limited (SHILPAMED) stock clears its 6M resistance trendline, moving up 5% intraday to ₹759.25.
Shilpa Medicare Limited (SHILPAMED) stock clears its 6M resistance trendline, gaining 11% intraday to ₹717.1. This breakout is driven by strong 1QFY27 earnings.
Shilpa Medicare Ltd reports a strong 1QFY27 with revenue up 43% YoY and EBITDA growing 42%, driven by robust performance across its key verticals.
Shilpa Medicare Limited (NSE: SHILPAMED) stock moves up 5% intraday, approaching resistance at ₹635. The stock is 0.
Shilpa Medicare Limited (NSE: SHILPAMED) stock moves up 5% intraday, approaching resistance at ₹623, backed by partnership expansion with Orion Corporation f.
Shilpa Medicare Limited (NSE: SHILPAMED) is down 5% intraday at ₹565.0, showing pressure after breakout.
Shilpa Medicare Limited (NSE: SHILPAMED) stock breaks out, gaining 5% intraday to ₹605.0, backed by expanded partnership with Orion Corporation for Nivolumab.
Shilpa Medicare Limited (NSE: SHILPAMED) announces expanded partnership with Orion Corporation for developing and supplying nivolumab biosimilar in Europe.